LivaNova (NASDAQ:LIVN) Trading 4% Higher – Still a Buy?

Shares of LivaNova PLC (NASDAQ:LIVN) rose 4% during trading on Monday . The company traded as high as $49.18 and last traded at $49.33. Approximately 235,591 shares traded hands during trading, a decline of 47% from the average daily volume of 442,709 shares. The stock had previously closed at $47.44.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LIVN. Mizuho reduced their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday. Stifel Nicolaus decreased their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC decreased their price objective on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday. Finally, StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $63.67.

LivaNova Trading Down 0.6 %

The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of 98.69 and a beta of 1.00. The firm’s 50 day moving average is $47.78 and its 200 day moving average is $49.62. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently made changes to their positions in LIVN. Russell Investments Group Ltd. lifted its position in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after acquiring an additional 219 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after acquiring an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division lifted its position in shares of LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after acquiring an additional 720 shares in the last quarter. Vestcor Inc purchased a new stake in shares of LivaNova in the 4th quarter valued at approximately $204,000. Finally, Optimize Financial Inc purchased a new stake in shares of LivaNova in the 4th quarter valued at approximately $208,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.